E-LIB Suche - Ergebnisse für: Demuth

1

P427 Efficacy and safety of vedolizumab and adalimumab in A..:

Kim, J S ; Leung, W K ; Wu, D C...
Journal of Crohn's and Colitis. 15 (2021) Supplement_1 - p. S431-S432 , 2021

Link: https://doi.org/10.1093/..

2

DOP55 A real-world comparison of the effectiveness and safe..:

Mantzaris, G ; Bressler, B ; Kopylov, U...
Journal of Crohn's and Colitis. 14 (2020) Supplement_1 - p. S092-S094 , 2020

Link: https://doi.org/10.1093/..

3

P387 Real-world clinical outcomes of biologic-naïve non-com..:

Yarur, A ; Mantzaris, G J ; Kopylov, U...
Journal of Crohn's and Colitis. 14 (2020) Supplement_1 - p. S360-S361 , 2020

Link: https://doi.org/10.1093/..

4

P574 Incidence and indicators of suboptimal response to tum..:

Li, J ; Li, Z ; Hu, P...
Journal of Crohn's and Colitis. 14 (2020) Supplement_1 - p. S483-S484 , 2020

Link: https://doi.org/10.1093/..

5

P419 Clinical effectiveness and safety of first-line biolog..:

Bressler, B ; Yarur, A ; Kopylov, U...
Journal of Crohn's and Colitis. 14 (2020) Supplement_1 - p. S381-S382 , 2020

Link: https://doi.org/10.1093/..

6

P621 Real-world effectiveness and safety of vedolizumab and..:

Bressler, B ; Mantzaris, G ; Silverberg, M...
Journal of Crohn's and Colitis. 13 (2019) Supplement_1 - p. S427-S428 , 2019

Link: https://doi.org/10.1093/..

7

P537 The impact of early disease control with vedolizumab o..:

Dulai, P ; Peyrin-Biroulet, L ; Hahn, K...
Journal of Crohn's and Colitis. 13 (2019) Supplement_1 - p. S382-S383 , 2019

Link: https://doi.org/10.1093/..

8

P573 Real-world effectiveness and safety of vedolizumab and..:

Yarur, A ; Mantzaris, G ; Silverberg, M...
Journal of Crohn's and Colitis. 13 (2019) Supplement_1 - p. S400-S401 , 2019

Link: https://doi.org/10.1093/..

9

P432 Barriers to prescribing anti-TNF therapy in inflammato..:

Ye, B D ; Yamamoto Furusho, J K ; Rana Qasim Khan, M...
Journal of Crohn's and Colitis. 13 (2019) Supplement_1 - p. S324-S325 , 2019

Link: https://doi.org/10.1093/..

10

P546 Vedolizumab outcomes in real-world bio-naive ulcerativ..:

Bressler, B ; Greenup, A -J ; Bassel, M...
Journal of Crohn's and Colitis. 12 (2018) supplement_1 - p. S382-S382 , 2018

Link: https://doi.org/10.1093/..

11

PGI4 - REAL-WORLD TRENDS IN CLINICAL CHARACTERISTICS OF INF..:

Weil, C. ; Chodick, G. ; Shalev, V....
Value in Health. 21 (2018) - p. S142 , 2018

Link: https://doi.org/10.1016/..

12

DOP002 Vedolizumab treatment persistence up to 3 years: pos..:

Vermeire, S ; Loftus Jr, E V ; Khalid, J M...
Journal of Crohn's and Colitis. 12 (2018) supplement_1 - p. S030-S031 , 2018

Link: https://doi.org/10.1093/..

13

P330 Discontinuation of corticosteroids among ulcerative co..:

Patel, H. ; Chastek, B. ; Null, K.D..
Journal of Crohn's and Colitis. 11 (2017) suppl_1 - p. S245-S246 , 2017

Link: https://doi.org/10.1093/..

14

P531 Discontinuation of corticosteroids among Crohn's disea..:

Patel, H. ; Chastek, B. ; Null, K.D..
Journal of Crohn's and Colitis. 11 (2017) suppl_1 - p. S350-S350 , 2017

Link: https://doi.org/10.1093/..

15

P466 Real world effectiveness of vedolizumab over one year ..:

Schreiber, S. ; Dignass, A. ; Peyrin-Biroulet, L....
Journal of Crohn's and Colitis. 11 (2017) suppl_1 - p. S315-S315 , 2017

Link: https://doi.org/10.1093/..